Dopamine receptor antagonist thioridazine inhibits tumor growth in a murine breast cancer model

Molecular Medicine Reports

Volumn 12, Issue 3, 2015, Pages 4103-4108

  Yin, Tao ^a   He, Sisi ^a   Shen, Guobo ^a   Ye, Tinghong ^a   Guo, Fuchun ^a   Wang, Yongsheng ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Breast cancer; Thioridazine

Indexed keywords

PROTEIN KINASE B; STAT3 PROTEIN; THIORIDAZINE; DOPAMINE RECEPTOR BLOCKING AGENT; KI 67 ANTIGEN; TRANSCRIPTION FACTOR RELA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; DISEASE MODEL; DRUG EFFECTS; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; VASCULARIZATION;

MURINAE;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; KI-67 ANTIGEN; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; STAT3 TRANSCRIPTION FACTOR; THIORIDAZINE; TRANSCRIPTION FACTOR RELA;

EID: 84935499417     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3967     Document Type: Article

References (28)

1. Schuller HM, Al-Wadei H, Ullah MF and Plummer HK III: Regulation of pancreatic cancer by neuropsychological stress responses: a novel target for intervention. Carcinogenesis 33:191-196, 2012.
2. Thaker PH, Han LY, Kamat AA, et al: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12:939-944, 2006.
3. Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, et al: Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29:2645-2652, 2011.
4. Lemeshow S, Sørensen HT, Phillips G, et al: β-blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 20:2273-2279, 2011.
5. Grytli HH, Fagerland M W, Fosså SD, et al: Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate 73:250-260, 2013.
6. Magnon C, Hall SJ, Lin J, et al: Autonomic nerve development contributes to prostate cancer progression. Science 341:1236361, 2013.
7. Sarkar DK, Zhang C, Murugan S, et al: Transplantation of β-endorphin neurons into the hypothalamus promotes immune function and restricts the growth and metastasis of mammary carcinoma. Cancer Res 71:6282-6291, 2011.
8. Yamazaki S, Ema H, Karlsson G, et al: Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 147:1146-1158, 2011.
9. Lucas D, Scheiermann C, Chow A, et al: Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration. Nat Med 19:695-703, 2013.
10. Sibley DR, Monsma FJ Jr: Molecular biology of dopamine receptors. Trends Pharmacol Sci 13:61-69, 1992.
11. González H, Contreras F, Prado C, et al: Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's Disease. J Immunol 190:5048-5056, 2013.
12. Pacheco R, Prado CE, Barrientos MJ and Bernales S: Role of dopamine in the physiology of T-cells and dendritic cells. J Neuroimmunol 216:8-19, 2009.
13. Saha B, Mondal AC, Basu S and Dasgupta PS: Circulating dopamine level, in lung carcinoma patients, inhibits proliferation and cytotoxicity of CD4+ and CD8+ T cells by D1 dopamine receptors: an in vitro analysis. Int Immunopharmacol 1:1363-1374, 2001.
14. Sachlos E, Risueño RM, Laronde S, et al: Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 149:1284-1297, 2012.
15. Seeman P and Lee T: Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217-1219, 1975.
16. Ly KL, Chidgey J, Addington-Hall J and Hotopf M: Depression in palliative care: a systematic review. Part 2. Treatment. Palliat Med 16:279-284, 2002.
17. Zhukovsky DS: Fever and sweats in the patient with advanced cancer. Hematol Oncol Clin North Am 16:579-588, 2002.
18. Rho SB, Kim BR and Kang S: A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol 120:121-127, 2011.
19. Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550-562, 2009.
20. Osaki M. Oshimura M and Ito H: PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9:667-676, 2004.
21. Corvinus FM, Orth C, Moriggl R, et al: Persistent STAT3 activation in colon growth. Neoplasia 7:545-555, 2005.
22. Sherry MM, Reeves A, Wu JK and Cochran BH: STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 27:2383-2392, 2009.
23. Bassères DS and Baldwin AS: Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25:6817-6830, 2006.
24. Lam LT, Davis RE, Pierce J, et al: Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 11:28-40, 2005.
25. Weis SM and Cheresh DA: Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17:1359-1370, 2011.
26. Byun HJ, Lee JH, Kim BR, et al: Anti-angiogenic effects of thioridazine involving the FAK-mTOR pathway. Microvasc Res 84:227-234, 2012.
27. Lechertier T and Hodivala-Dilke K: Focal adhesion kinase and tumour angiogenesis. J Pathol 226:404-412, 2012.
28. Ponti D, Costa A, Zaffaroni N, et al: Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65:5506-5511, 2005.